PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA. Details of the presentation are as follows: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic WindowSes ...

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team partici ...

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team partici ...

文章核心观点 公司公布SON - 1010与阿替利珠单抗联用的SB221研究积极安全性结果，研究可推进至扩展阶段，SON - 1010展现出临床获益和潜在协同治疗效果 [1] 分组1：SON - 1010与阿替利珠单抗联用研究结果 - 铂耐药卵巢癌患者中SON - 1010与阿替利珠单抗联用最大耐受剂量设为1200 ng/kg，无剂量限制性毒性和细胞因子释放综合征证据 [1] - 15例可评估患者中5例（33%）在给药4个月后疾病稳定，4例持续超过6个月 [1] - 一名接受最大耐受剂量治疗的铂耐药卵巢癌患者按RECIST标准出现部分缓解，肿瘤大小较基线降低44%，CA 125生物标志物降低超2倍 [1] - 剂量扩展阶段疲劳、发热和胃肠道症状是最常见不良反应，剂量递增阶段唯一相关严重不良事件是2级肺炎 [3] - 19例已给药患者中，15例可评估患者在首次随访CT扫描时有8例（53%）疾病稳定，4个月时有5例（33%）仍稳定 [5] 分组2：研究意义与展望 - 现有免疫药物治疗铂耐药卵巢癌疗效不佳，SON - 1010与免疫检查点抑制剂联用使患者肿瘤缩小令人兴奋，研究将进入下一阶段 [4] - 高剂量SON - 1010与阿替利珠单抗联用毒性极小，可能实现该细胞因子在临床前模型中的抗肿瘤效果，与检查点抑制剂或化疗可能有协同治疗作用 [5] - 此次安全性数据发布是公司临床开发重要里程碑，公司将继续评估患者长期安全性和肿瘤反应，并寻求合作支持SON - 1010后期开发 [6] 分组3：SON - 1010介绍 - SON - 1010是候选免疫治疗重组药物，将未修饰单链人IL - 12与单链抗体片段A10m3的白蛋白结合域相连 [7] - FHAB技术可靶向肿瘤和淋巴组织，为IL - 12等免疫调节剂提供剂量节省机制，有望改善安全性和有效性 [7] - SON - 1010旨在将IL - 12递送至局部肿瘤组织，激活免疫细胞反应，增加肿瘤细胞上PD - L1的产生 [7] 分组4：SB221 Phase 1b/2a试验介绍 - SB221是全球多中心、剂量递增和随机概念验证研究，评估SON - 1010单独或与阿替利珠单抗联用的安全性、耐受性、药代动力学、药效学和有效性 [8] - 研究第一部分快速确定联用最大耐受剂量，扩大数据集以显示在铂耐药卵巢癌中的疗效可能性，第二部分评估联用相对SON - 1010单药或标准治疗的疗效改善潜力 [8] 分组5：公司介绍 - 公司是专注肿瘤学的生物技术公司，拥有FHAB专有平台，用于开发单功能或双功能靶向生物药物 [10] - 公司主要项目SON - 1010正与罗氏合作评估用于治疗铂耐药卵巢癌，第二个项目SON - 1210将与肉瘤肿瘤中心合作开展胰腺癌治疗研究 [11]

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC), without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months post-initiation of dosing was seen in 5 of 15 evaluable patients (33%), with 4 continuing beyond 6 months One ...

PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here. The corporate update video is also accessible on the Events page under the Investors section of the Company's website (www.sonnetbio.com). About Sonnet BioTherapeutics Holdings, Inc. Forward-Lo ...

Mr. Rao, Interim CEO, commented, "We are heartbroken by this unexpected, tragic loss. Pankaj was a respected leader and visionary throughout his ten years at Sonnet. His unwavering belief in Sonnet's technology and dedication to providing much needed treatment options to patients has continued to propel Sonnet to where it is today. Our support and deepest condolences are with his family and loved ones during this extraordinarily sad time." PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherap ...

SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS) The Safety Review Committee found no unexpected toxicities in early dosing of SON-1010 in the first 7 patients at the maximum tolerated dose (MTD), paving the way for full enrollment of up to 18 patients The a ...

文章核心观点 - 公司获美国专利商标局（USPTO）颁发的IL - 18变体蛋白领域第二项专利 ，涵盖变体人IL - 18蛋白氨基酸序列 ，有望增强知识产权地位并探索授权机会 ，其药物候选物SON - 1411等具有治疗肿瘤潜力 [1] 公司专利情况 - 美国专利商标局（USPTO）向公司颁发IL - 18变体蛋白领域第二项专利 ，该专利涵盖变体人IL - 18（hIL - 18）蛋白 ，包括在特定位置有氨基酸取代的hIL - 18蛋白 [1] - 专利涵盖的氨基酸取代位置相对于人野生型IL - 18为Y1W、Y1K、M51Y、M51S、M60W、S105E和D110Y [1] - 专利为IL - 18独立于公司FHAB平台专利资产的授权开辟潜在机会 [1] 公司药物研发情况 SON - 1411 - SON - 1411是候选免疫治疗重组药物 ，将取代SON - 1410 ，二者区别在于SON - 1411的IL - 18结构域经诱变修饰 ，保留与IL - 18受体结合 ，抑制或消除与IL - 18结合蛋白结合 [2] - SON - 1411是专有双功能融合蛋白 ，由IL - 18与单链野生型IL - 12结合 ，并与公司FHAB平台相连 ，旨在将IL - 18和IL - 12递送至局部肿瘤组织 ，激活免疫细胞反应 [1][3] - 几种癌症如非小细胞肺癌、黑色素瘤、头颈癌、肉瘤和一些妇科癌症与SON - 1411的治疗方法特别相关 [3] 其他药物 - 公司此前报告生成两种新药候选物SON - 1411和SON - 1400 ，均含重组人白细胞介素 - 18（IL - 18）的变体版本 [1] - 公司的SON - 1010（IL - 12 - FHAB）正在开发用于治疗晚期实体瘤、某些类型肉瘤和铂耐药卵巢癌（PROC） ，正与罗氏进行1/2a期研究 [4] - 公司的SON - 1210（IL12 - FHAB - IL15双功能药物）用于实体瘤 ，正与创新免疫肿瘤学联盟（IIOC）合作评估 ，计划开展局部晚期或转移性胰腺导管腺癌（PDAC）的1/2a期研究 [4] - 公司的SON - 080项目是低剂量重组人IL - 6 ，用于化疗诱导的周围神经病变（CIPN）和糖尿病周围神经病变（DPN） ，已与Alkem Laboratories达成许可协议 [5] 公司平台技术 - 公司拥有专有平台FHAB（完全人白蛋白结合） ，利用完全人单链抗体片段（scFv）与人类血清白蛋白（HSA）结合 ，运输至靶组织 ，可优化免疫调节生物药物的安全性和有效性 [4] - FHAB平台是模块化、即插即用构建体的基础 ，可增强一系列大分子治疗类别 ，包括细胞因子、肽、抗体和疫苗 [4]

On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. As part of the event, Pankaj Mohan, Ph.D., Founder and Chief Executive Officer of Sonnet, presented the top five reasons of why he believes the investment community and i ...